RecruitingNCT05974904

Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

Association of High-sensitivity C-reactive Protein to Albumin Ratio with Metabolic Dysfunction-associated Fatty Liver Disease and Liver Fibrosis: a Cross-sectional Study


Sponsor

Chongqing Medical University

Enrollment

7,000 participants

Start Date

Jul 18, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD). The main question\[s\] it aims to answer are: \[question 1\] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? \[question 2\] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying high-sensitivity C-reactive protein to albumin ratio for people with hepatic steatosis, liver fibrosis, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERhigh-sensitivity C-reactive protein to albumin ratio

High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.


Locations(1)

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05974904


Related Trials